Physician profile
Thomas E Gearhard
NPI 1538159603
$974.02
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $17.03 · 2021: $34.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $179.03 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $171.91 | 2019 | |
| Pfizer INC. | $109.89 | 2019 | |
| Novo Nordisk INC | $93.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.14 | 2019 | |
| Lilly USA, LLC | $76.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.38 | 2019 | |
| Amarin Pharma, INC. | $19.45 | 2019 | |
| Abbott Laboratories | $19.32 | 2019 | |
| Astellas Pharma US INC | $17.72 | 2019 | |
| Endo Pharmaceuticals INC. | $17.03 | 2020 | |
| Daiichi Sankyo INC. | $15.90 | 2019 | |
| Merck Sharp & Dohme LLC | $15.32 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.14 | 2019 | |
| Avanos Medical | $15.10 | 2019 | |
| Glaxosmithkline, LLC. | $14.86 | 2021 | |
| Sanofi Pasteur INC. | $13.02 | 2019 | |
| Aytu Biopharma, INC. | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gearhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.